Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health Cervical Cancer Screening Coverage | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentOscar HealthPolicy N/A

    Cervical Cancer Screening

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage criteria and limits for cervical cancer screening (Pap cytology, high-risk HPV testing, and co-testing) for individuals with a cervix, including special populations such as immunocompromised individuals and those with prior abnormal results.

    Policy Summary
    PayerOscar Health
    PolicyCervical Cancer Screening
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionDocument and submit appropriate screening and reflex testing (same‑specimen reflex cytology or genotyping) and ensure coding supports performed services.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    21-65 yearsUSPSTF recommended screening age range
    30-65Age range with multiple acceptable options
    5yPrimary hr-HPV testing interval
    AnnualImmunocompromised screening frequency
    <21 / >65 (routine)Not indicated
    ≥25ySurveillance after high-grade treatment

    Coverage Criteria — Cervical Cancer Screening

    Immunocompromised or immunosuppressed individuals

    Covered when ANY of the following are met:

    Immunocompromised screening options: a) Annual cervical cytology testing for individuals of all ages; OR b) Co-testing (cervical cytology and high-risk HPV testing) once every 3 years for individuals 30 years of age or older.

    Individuals 21 to 29 years of age

    Covered when ALL of the following are met:

    Age 21-29 cytology: Cervical cancer screening once every 3 years using conventional or liquid-based Papanicolaou (Pap) smears.3 years

    HPV primary testing not preferred for this age group per policy guidance.

    Individuals 30 to 65 years of age

    Policy Summary
    PayerOscar Health
    PolicyCervical Cancer Screening
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionDocument and submit appropriate screening and reflex testing (same‑specimen reflex cytology or genotyping) and ensure coding supports performed services.
    SourceLink
    On This Page
    Coverage Criteria — Cervical Cancer ScreeningProcedure and Billing CodesProvider Actions, Documentation, and Billing GuidanceBackground and ScopeDefinitions and Key TermsPolicy Revision History

    Covered when ANY of the following are met:

    Age 30-65 options: a) Conventional or liquid-based Pap smear once every 3 years; OR b) Cervical cancer screening using the high-risk HPV (hr-HPV) test alone once every 5 years; OR c) Co-testing (cytology with concurrent hr-HPV testing) once every 5 years.3 years or 5 years depending on method

    Co-testing frequency listed as 5 years in policy text.

    Pooled hr-HPV positive individuals

    Genotyping for HPV-16/18: Nucleic acid testing for high-risk strains HPV-16 and HPV-18 meets criteria for individuals who are pooled hr-HPV positive.

    Genotyping to stratify risk and guide further management.

    Individuals <=65 years with prior abnormal/ high-risk features

    Covered when ANY of the following are met:

    Annual screening for prior abnormal: Annual cervical cancer screening by Pap smear or hr-HPV testing meets criteria in individuals 65 years of age or younger who had a previous abnormal cytology result and/or who were positive for HPV, or who are at high risk (e.g., organ transplant, in utero DES exposure).Annual

    Applies up to age 65 per policy language.

    Not indicated / does not meet criteria

    Age <21: Cervical cancer screening for individuals less than 21 years of age does not meet criteria (except special high-risk situations covered elsewhere).

    Policy statement III.7.

    >65 not high-risk: Routine cervical cancer screening for individuals over 65 years who are not immunocompromised, immunosuppressed, or high-risk (no prior abnormal cytology or HPV) does not meet criteria.

    Policy statement III.8.

    Post-hysterectomy without history: Individuals who have undergone surgical removal of the uterus and cervix and who have no history of cervical cancer or precancer: screening at any age does not meet criteria.

    Policy statement III.9.

    Other technologies: All other technologies not discussed in the policy do not meet criteria due to lack of sufficient published evidence.

    Policy statement III.10.

    Routine screening of average-risk individuals

    Covered when meeting guideline age and interval recommendations:

    USPSTF routine screening ages: Individuals aged 21–29: cytology alone every 3 years; individuals aged 30–65: cytology every 3 years OR primary hr-HPV testing every 5 years OR cotesting every 5 years.age-based

    USPSTF Grade A recommendation for persons 21–65.

    Not recommended (routine) populations

    Not covered routinely when:

    Age-based stopping: Women younger than 21 or older than 65 with adequate prior screening, and women with hysterectomy for benign disease: do not screen routinely.age-based

    USPSTF recommends against routine screening in these groups (Grade D).

    Immunocompromised / special population screening

    Covered with intensified surveillance for immunocompromised individuals:

    Solid organ transplant and other immunocompromised: Begin earlier and screen more frequently: cytology recommended if younger than 30 years; co-testing preferred if ≥30 years; if using cytology alone perform annual cytology until three consecutive normals then every 3 years; continue screening beyond age 65 based on shared decision-making and life expectancy.condition-based

    Applies to transplant recipients, HSCT with GVHD, IBD or rheumatologic disease on immunosuppressants per ASCCP guidance.

    Management after positive HPV or abnormal cytology

    Risk-based management and reflex testing requirements:

    Reflex testing for positive primary HPV: All positive primary HPV screening tests should have additional reflex triage testing (eg, cytology) performed from the same laboratory specimen; if reflex testing is not feasible and HPV 16/18 is positive, refer to colposcopy and obtain triage testing at colposcopy.test-result-based

    HPV 16/18 positivity carries highest CIN3+ risk and warrants expedited evaluation.

    Expedited treatment criteria: Expedited treatment without preceding confirmatory biopsy is preferred for nonpregnant patients ≥25 years when immediate risk of CIN3+ ≥60% (eg, HSIL cytology with HPV16 positive); acceptable for risks 25–60% depending on shared decision-making.risk-threshold

    Expedited treatment requires cytology to have been performed.

    Post-treatment surveillance: Continue surveillance with HPV testing or cotesting at 3-year intervals for at least 25 years after treatment of histologic HSIL, CIN2, CIN3, or AIS; continued surveillance beyond 25 years is acceptable based on life expectancy and screening ability.time-based

    ASCCP and ACOG endorse extended long-term surveillance.

    Self-sampling (vaginal HPV) for screening

    Acceptable alternatives and follow-up requirements:

    Self-collected vaginal HPV specimens: Clinician-collected cervical specimens are preferred; self-collected vaginal specimens are acceptable for screening in asymptomatic average-risk individuals. If self-sampled HPV is negative, repeat testing in 3 years; if positive for HPV16/18, direct referral to colposcopy with concurrent cytology collection; if positive for other hr types, obtain clinician-collected cervical specimen for cytology or dual stain for further management.test-result-based

    Recommendations based on Enduring Consensus 2025 update; genotype-specific follow-up pathways described.

    Covered screening, triage, and post-treatment surveillance

    General coverage approach based on referenced guidelines:

    Accepted screening strategies for average-risk: For average-risk persons: cytology alone every 3 years (age 21-29), and for persons 30-65 either cytology every 3 years, primary HPV testing every 5 years, or cotesting every 5 years; societies recommend primary HPV testing every 5 years for ages 25-65 in maximal-resource settings.age-based

    References include CDC, ASCO, ACOG.

    Reflex triage for positive HPV: All positive primary HPV screening tests should have additional reflex triage testing from the same laboratory specimen (eg, reflex cytology or genotyping); if genotyping for HPV-16/18 is positive, proceed to colposcopy even if cytology is negative.HPV positive

    ACOG and CDC recommend reflex testing; ASCO recommends reflex genotyping or cytology.

    Surveillance after treatment for high-grade disease: Continued surveillance with HPV testing or cotesting at 3-year intervals for at least 25 years after treatment for histologic HSIL, CIN2, CIN3, or AIS; surveillance with cytology alone acceptable only if HPV testing not feasible.post-treatment

    ACOG states elevated risk persists for ≥25 years.

    HIV-specific screening and follow-up

    Persons with HIV — CDC/HHS specific recommendations:

    Women with HIV aged 21-29: Pap test at HIV diagnosis and every 12 months; if three consecutive Pap tests are normal, interval may extend to every 3 years; co-testing not recommended for <30.HIV+, age 21-29

    HHS guidance.

    Women with HIV aged ≥30: Either annual Pap testing with extension to every 3 years after three normal annual tests, or baseline Pap and HPV co-testing with subsequent 3-year intervals if negative; positive HPV-16/18 should prompt colposcopy.HIV+, age ≥30

    HHS guidance includes genotype-directed colposcopy.

    Resource-stratified screening and management

    ASCO resource-stratified recommendations (selected):

    Maximal-resource settings: HPV DNA testing every 5 years from age 25 to 65; triage with reflex genotyping for HPV16/18 and/or cytology; abnormal triage (≥ASC-US or HPV16/18) → colposcopy and biopsy; repeat HPV at 12 months if triage negative.maximal resources

    ASCO 2022 recommendations.

    Enhanced-resource settings: HPV DNA testing every 5 years age 30-65; genotyping/reflex cytology triage; abnormal triage → colposcopy; repeat HPV at 12 months if triage negative; two consecutive negatives may extend screening interval.enhanced resources

    ASCO 2022.

    Limited/basic settings: Screening prioritized to ages 30-49 with intervals of up to every 10 years depending on resources; positive HPV → reflex cytology/genotyping or VIA/VAT and treatment pathways described; follow-up at 12 months after treatment.limited/basic resources

    ASCO resource-stratified guidance.

    Routine cervical cancer screening DOES NOT MEET CRITERIA for individuals over 65 years who are not immunocompromised, immunosuppressed, or otherwise at high risk (for example, those without a history of abnormal cytology or prior positive hr‑HPV). This policy statement reflects the limitation in Section III that routine screening in this population is not covered absent qualifying risk factors.

    Screening is not beneficial for people who no longer have a cervix as a result of a hysterectomy performed for benign disease. The National Cancer Institute and this policy state that cervical cancer screening in women without a cervix for benign indications does not meet criteria.

    Testing for low‑risk HPV types (the non‑oncogenic types associated with genital warts) is not recommended. The American Academy of Family Physicians advises: 'Don't perform low‑risk human papillomavirus (HPV) testing' because identification of low‑risk types does not alter clinical management or predict progression to cervical precancer or cancer.

    No additional explicit exclusions are listed in this section of the policy beyond the specified age, post‑hysterectomy, and technology exclusions noted elsewhere. Procedure code guidance (e.g., G0476) appears in the coding section but does not by itself create new exclusions.

    For clinical situations not specifically addressed by the policy's covered criteria, cervical cancer screening does not meet criteria unless coverage is supported by another policy section or an applicable guideline. The policy notes that technologies not discussed in the document do not meet criteria due to lack of sufficient published evidence.

    Routine screening outside the guideline age ranges—specifically, screening individuals younger than 21 years or older than 65 years with adequate prior negative screening—is considered not beneficial per USPSTF and the National Cancer Institute and therefore does not meet criteria for routine screening.

    Testing specifically for low‑risk HPV types (those that cause genital warts) is not indicated for cervical cancer screening because these types are not associated with progression to cervical precancer or cancer and identification would not change management.

    There are no explicit 'not medically necessary' statements listed in this section beyond the age, post‑hysterectomy, and technology limitations already described. The policy's not‑medically‑necessary listings reiterate that technologies not discussed lack sufficient evidence to meet criteria.

    Procedure and Billing Codes

    Covered HPV NAAT CPT CodesCPTCovered
    87624Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types, pooled result.
    87625Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), types 16 and 18 only, includes type 45, if performed.
    Covered Cytopathology CPT CodesCPTCovered
    88141Cytopathology, cervical or vaginal (any reporting system), requiring interpretation by physician.
    88142Cytopathology, cervical or vaginal, collected in preservative fluid, automated thin layer preparation; manual screening under physician supervision.
    88147Cytopathology smears, cervical or vaginal; screening by automated system under physician supervision.
    88148Cytopathology smears, cervical or vaginal; screening by automated system with manual rescreening under physician supervision.
    88150Cytopathology, slides, cervical or vaginal; manual screening under physician supervision.
    88152Cytopathology, slides, cervical or vaginal; with manual screening and computer-assisted rescreening under physician supervision.
    88153Cytopathology, slides, cervical or vaginal; with manual screening and rescreening under physician supervision.
    88164Cytopathology, slides, cervical or vaginal (the Bethesda System); manual screening under physician supervision.
    88165Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and rescreening under physician supervision.
    88166Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and computer-assisted rescreening under physician supervision.
    1–10 of 13
    1/2
    Covered HCPCS Screening Cytology CodesHCPCSCovered
    G0123Screening cytopathology, preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision.
    G0124Screening cytopathology, cervical or vaginal, collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician.
    G0141Screening cytopathology smears, cervical or vaginal, performed by automated system, with manual rescreening, requiring interpretation by physician.
    Covered cytopathology CPT codesCPTCovered
    88152Cytopathology, slides, cervical or vaginal; with manual screening and computer-assisted rescreening under physician supervision.
    88153Cytopathology, slides, cervical or vaginal; with manual screening and rescreening under physician supervision.
    88164Cytopathology, slides, cervical or vaginal (the Bethesda System); manual screening under physician supervision.
    88165Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and rescreening under physician supervision.
    88166Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and computer-assisted rescreening under physician supervision.
    88167Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and computer-assisted rescreening using cell selection and review under physician supervision.
    88174Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; screening by automated system, under physician supervision.
    88175Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with screening by automated system and manual rescreening or review, under physician supervision.
    Screening cytopathology G-codesHCPCSCovered
    G0123Preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision.
    G0124Screening cytopathology, cervical or vaginal, collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician.
    G0141Screening cytopathology smears, cervical or vaginal, performed by automated system, with manual rescreening, requiring interpretation by physician.
    HPV and Pap screening codes (G/P/Q)mixedCovered
    G0476Infectious agent detection by nucleic acid (DNA or RNA); human papillomavirus (hpv), high-risk types for cervical cancer screening, must be performed in addition to pap test.
    P3000Screening Papanicolaou smear, cervical or vaginal, up to three smears, by technician under physician supervision.
    P3001Screening Papanicolaou smear, cervical or vaginal, up to three smears, requiring interpretation by physician.
    Q0091Screening Papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory.

    Provider Actions, Documentation, and Billing Guidance

    Prior Authorization

    Authorization and medical necessity

    Coverage and reimbursement are conditioned on meeting applicable authorization and medical necessity requirements and the member's state of residence; services must meet those requirements to be reimbursed.

    Prior Authorization

    Reflex testing and colposcopy workflow

    All positive primary HPV screening tests require reflex triage testing (e.g., reflex cytology or genotyping) performed from the same laboratory specimen; if same-specimen reflex testing is not feasible and HPV-16/18 is positive, proceed directly to colposcopy and collect an additional triage specimen at that visit.

    • Perform reflex cytology or genotyping from the same specimen for every positive primary HPV test.
    • If same-specimen reflex testing is not feasible and HPV 16 or 18 is positive, refer to colposcopy and obtain additional triage testing at colposcopy.
    Billing Rule

    Procedure coding to submit

    Submit claims with the applicable HPV nucleic acid and cytopathology procedure codes listed in the policy for screening, reflex, cotesting, and cytology services.

    • Include HPV NAAT codes 87624, 87625 as applicable.
    • Include cytopathology CPT and HCPCS codes (e.g., 88141–88175, G0123, G0124, G0141) when cytology or automated screening/rescreening is performed.
    Prior Authorization

    Prior authorization for listed codes

    This policy does not list explicit prior authorization requirements for the procedure codes shown in the policy section.

    Note

    Follow screening criteria and document rationale

    Providers are expected to follow the policy's screening criteria and reflex testing requirements when managing HPV-positive or abnormal cytology results; document rationale and test results to support medical necessity decisions.

    Step Therapy

    Risk-based triage (non‑pharmacologic) workflow

    When managing positive HPV or abnormal cytology, follow the policy's risk-based pathways (reflex cytology/genotyping and colposcopy per genotype and cytology) rather than a stepwise pharmacologic step-therapy approach.

    Note
    Documentation Required

    Provider documentation obligation

    Providers must submit accurate documentation of services performed and code claims according to industry-standard coding guidelines; failure to follow coding/billing guidelines may result in denial or recoupment.

    • Code claims per CPT, HCPCS, ICD-10 and other applicable coding guidance.
    • Maintain documentation supporting services performed and medical necessity.
    Documentation Required

    Required documentation for positive HPV tests and cessation

    Ensure reflex triage testing is performed from the same specimen for positive primary HPV tests and that genotype (HPV‑16/18) results are documented when obtained; document prior screening history when making cessation decisions.

    • Document reflex cytology or genotyping performed from the same specimen for every positive primary HPV screen.
    • Record HPV genotype (notably HPV‑16/18) results when performed.
    • Document prior screening history when deciding to stop screening.
    Documentation Required

    Reflex testing documentation

    Document that reflex triage testing (e.g., reflex cytology or genotyping) was performed from the same laboratory specimen for all positive primary HPV screening tests; if reflex testing was not feasible, document that and the actions taken (eg, direct colposcopy).

    • Support claims by showing same-specimen reflex testing occurred or why it was not feasible.
    • If reflex testing was not feasible and colposcopy was performed, document collection of an additional triage specimen at colposcopy.
    Note
    Billing Rule

    Pap test documentation when billing G0476

    When billing G0476, document that a Pap test was performed because G0476 specifies HPV nucleic acid testing for cervical cancer screening must be performed in addition to a Pap test.

    • Include documentation of Pap test collection and interpretation when submitting claims with G0476.
    Denial Risk

    Coding and documentation compliance risk

    Claims may be denied or recouped if coding/billing guidelines or reimbursement policies are not followed or if appropriate documentation is not provided to support the service.

    Denial Risk

    Age‑based screening denial risk

    Screening performed outside recommended age ranges — e.g., routine screening for individuals younger than 21 or older than 65 with adequate prior screening — is not recommended by USPSTF and may be denied if not justified by documented risk factors.

    • Provide documentation of high-risk conditions if screening outside recommended age ranges is performed.
    Denial Risk

    Follow applicable government policies

    If there is a conflict between this policy and an applicable government policy (e.g., Medicare LCD/NCD or state Medicaid), the government policy governs determinations; failure to follow the controlling government policy may risk denial.

    • Check applicable Medicare/Medicaid local and national coverage policies for members covered by those programs.
    Billing Rule

    Combination testing requirement for G0476

    G0476 requires that high‑risk HPV nucleic acid testing be performed in addition to a Pap test; failing to perform the required combination testing could affect billing and lead to denial.

    • When using G0476, ensure concurrent Pap test performance and documentation per the code description.

    Background and Scope

    Cervical cancer screening is intended to detect precancerous lesions and invasive cancer using Pap cytology, high‑risk HPV (hr‑HPV) testing, and colposcopy when indicated. These modalities are the basis for the coverage criteria, triage (including reflex cytology or genotyping), and post‑treatment surveillance strategies described in the policy.

    Definitions and Key Terms

    hr-HPV (High-risk human papillomavirus)
    DefinitionHigh-risk human papillomavirus (hr-HPV) — HPV types associated with cervical cancer (eg, types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68).
    Clinical relevancehr-HPV, particularly HPV-16 and HPV-18, carry the highest risk for CIN3+ and occult cancer and guide triage/management decisions (eg, colposcopy, expedited treatment).
    Use in screeningPrimary hr-HPV testing may be used alone for cervical cancer screening in eligible age groups (policy supports hr-HPV screening every 5 years for average-risk persons 30–65).
    Role in reflex testingPositive hr-HPV results require reflex triage testing (eg, cytology or genotyping) from the same specimen to inform risk-based management and colposcopy decisions.
    DES (Diethylstilbestrol)
    DefinitionDES — Diethylstilbestrol; in utero exposure associated with increased cervical cancer risk.
    Population impactIndividuals with in utero DES exposure are considered higher risk and may warrant intensified surveillance per policy.
    Context in policyListed in terminology table as a recognized risk factor informing coverage and surveillance recommendations for cervical screening.
    Reflex triage testing
    DefinitionReflex triage testing — Additional testing (eg, cytology) performed from the same laboratory specimen after a positive primary HPV test to inform risk-based management and colposcopy decisions.
    RequirementAll positive primary HPV screening tests should have reflex triage testing performed from the same specimen because findings may inform colposcopy practice.
    If not feasibleIf same-sample reflex testing is not feasible and HPV-16/18 is positive, proceed directly to colposcopy and collect triage testing at that time.
    Expedited treatment
    DefinitionExpedited treatment — Treatment without a preceding colposcopic biopsy demonstrating CIN2+; considered when immediate risk of CIN3+ ≥ 60% for nonpregnant patients (eg, HSIL cytology with HPV-16 positive in patients ≥25 years).
    Age/conditionPreferred for nonpregnant patients 25 years or older when immediate CIN3+ risk ≥ 60%; acceptable for risks 25–60% with shared decision-making.
    PrerequisiteExpedited treatment is only possible when cytology has been performed (reflex cytology recommended for HPV-positive screening results).
    Reflex testing
    DefinitionReflex testing — Additional laboratory testing (eg, cytology or HPV genotyping) performed on the same specimen after a positive primary HPV screening test to guide further management, including colposcopy decisions.
    PurposeCombines high-sensitivity HPV testing with high-specificity tests (eg, cytology) to allow precise, risk-based management.
    Policy expectationDocumentation should support that reflex testing was performed or was not feasible; if not feasible and HPV-16/18 positive, proceed to colposcopy and obtain triage specimen at that time.
    Triaging
    DefinitionTriaging — Using cytology results and/or HPV genotyping (notably HPV-16/18) to determine need for colposcopy, surveillance interval, or treatment.
    Genotype impactHPV-16 or HPV-18 positivity confers higher risk and often prompts direct colposcopy or expedited treatment pathways even when cytology is negative.
    Clinical applicationTriaging informs whether to observe, repeat testing, refer for colposcopy, or offer expedited treatment based on combined test results and patient history.
    G0476
    Code descriptionG0476 — Infectious agent detection by nucleic acid (DNA or RNA); human papillomavirus (HPV), high-risk types for cervical cancer screening; must be performed in addition to Pap test.
    Billing noteWhen billing G0476, documentation should indicate Pap test performance because the code description requires HPV testing to be performed in addition to Pap.
    Common useIncluded in the policy's listed HPV and Pap screening codes alongside other CPT/HCPCS codes relevant to screening and cytology.

    Policy Revision History

    2026-06-16publicationLatest

    Original documentation published and governance approved.